The effects of metformin on immune function.

The effects of metformin on immune function. - Metformin Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41133

Enrollment

Registered

2014-09-29

Start date

2014-06-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immunometabolism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy, > 18 years of age, no history of TB, no history of cardiac or renal disease

Exclusion criteria

Exclusion criteria: DM in first degree relatives, obesity (BMI > 25), use of medication

Design outcomes

Secondary

Measure	Time frame
• Gene expression and transcriptional analysis of samples with a strong focus on immunity, inflammation, epigenetic and metabolic related pathways. • Epigenetic modulation of gene and protein expression by metformin • Metabolic regulation of key energy sensors (AMPK, mTOR, AKT, PKA etc) by metformin	—

Primary

Measure	Time frame
The primary objective of the study is to evaluate the effects of orally administered metformin on the immune responses of stimulated peripheral blood mononuclear cells (PBMC*s) and macrophages from healthy individuals. The effects of metformin will be determined by measuring the ex-vivo responsiveness of leukocytes to various pathogens and inflammatory stimuli. The primary outcome of this measure is production of cytokines (for example TNF-a, IL-6, IL-10, IL-1β, IL-17, IL-22, IFN-γ secretion by ex vivo stimulated PBMCs.	—

Measure

Time frame

The primary objective of the study is to evaluate the effects of orally administered metformin on the immune responses of stimulated peripheral blood mononuclear cells (PBMC*s) and macrophages from healthy individuals. The effects of metformin will be determined by measuring the ex-vivo responsiveness of leukocytes to various pathogens and inflammatory stimuli. The primary outcome of this measure is production of cytokines (for example TNF-a, IL-6, IL-10, IL-1β, IL-17, IL-22, IFN-γ secretion by ex vivo stimulated PBMCs.

—

Countries

Netherlands

Outcome results